Oral IIb/IIIa Antiplatelet Development Winding Down; Four Companies Out
Executive Summary
Eight clinical development programs for oral glycoprotein IIb/IIIa receptor antagonists are being closed down in response to lack of compound efficacy.
You may also be interested in...
CombiChem Outside Collaborations May End After Purchase By DuPont
The future of CombiChem's existing collaborations is uncertain following DuPont's announcement that it will acquire the company for approximately $95 mil.
CombiChem Outside Collaborations May End After Purchase By DuPont
The future of CombiChem's existing collaborations is uncertain following DuPont's announcement that it will acquire the company for approximately $95 mil.
Quintiles Increases Contract Win Rate But Suffers From Halt Of Antiplatelets
Quintiles has won about 550 contract bid proposals for drug development work in the U.S. during the first seven months of 1999, according to figures on its success rate provided to analysts during a Sept. 17 conference call.